ABOUT THE
ALL4LIVER GRANT
The applications will be reviewed by an external review panel made up of experts globally (excluding the United States), recognized for their expertise in liver disease research, public health knowledge or patient advocacy work. Upon recommendation of the review panel, a Gilead grant review committee will make the final decision on which of the proposals to award grants.
Application Process
Grant application period has closed for 2021
Announcement of 2021 grantees
Early 2022
Grant application opens
Early 2023
Focus Area
01
Test. Driving testing for viral hepatitis
Despite the crucial role testing plays, there are many barriers to it, including insufficient awareness and education, stigma and discrimination, access to/cost of services and the fact that viral hepatitis can be asymptomatic for many years. The grant seeks to support insight-driven and integrated approaches to overcome these barriers and increase testing rates for viral hepatitis.
02
Link. Supporting linkage to care for people affected by viral hepatitis
While anyone can contract viral hepatitis, it disproportionately affects people and communities most underserved by traditional healthcare models. As a result, linkage to and retention within care can be challenging. The grant seeks to support creative and sustainable solutions to reach and engage key populations affected by viral hepatitis.
03
Prioritize. Putting viral hepatitis (back) on the public health agenda
COVID-19 took priority over other diseases the last few years, pushing viral hepatitis further down the political and healthcare agenda. The grant seeks to support innovative ideas to put viral hepatitis elimination targets firmly (back) on the agenda for policymakers and public health professionals, to help drive urgent action.
Eligibility Criteria
We welcome proposals from groups that meet the following criteria:
Grant proposal should demonstrate a well-structured project with clearly defined deliverable(s) and designed with sustainability (financing, longevity, scalability, and future replication) in mind.
Grant proposal should enable and support the engagement of stakeholders to foster multistakeholder collaboration (e.g., cross-disease collaboration, participation or partnership with healthcare providers or institutes) to ensure that eliminating viral hepatitis as a public health threat is a priority on national health agendas.
Grant proposal should demonstrate a defined and achievable approach to measuring impact against defined deliverable(s).
Reputation and track record of the applying organization will also be reviewed to ensure the applicant has the ability to execute the project, with good governance and budget control.
Funding Guidance:
Gilead funding may not be used to pay for or offset the cost of:
- Medications or purchase of medications
- Direct purchase of equipment/hardware, including but not limited to, mobile phones, laptops, motor vehicles and furniture etc.
- Direct medical expenses, including lab tests
- Existing deficits or debts
- Basic biomedical research, clinical research, or clinical trials
- Projects that directly influence or advance Gilead’s business including purchase, utilization, prescribing, formulary position, pricing, reimbursement, referral, recommendation, or payment for products
- Individuals, individual health care providers, policymakers or physician group practices
- Events or programs that have already occurred
- Government lobbying activities
Funding will not be provided to organizations that discriminate on the basis of race, color, gender, religion, disability, sexual orientation, gender identity or expression.
The approved grant amount will factor in the medium chosen, scale, project duration and cost of living across countries.
May team up with other groups for the execution of project but funding will be granted to one group as the project coordinator.
Up to 10% of the budget may be dedicated to impact reporting.
The selected project is required to conclude before 30 June 2025.
Submission:
All grant proposals must be submitted online through the Gilead grant portal.
Submissions need to be completed in English; applicants who need support in submitting their proposals in English can send in their queries through the grant portal.
Please tag Gilead ALL4LIVER Grant Program within the grants portal and specify which of the focus areas the proposal falls under.
These are general guiding principles. There may be additional eligibility requirement based on individual countries’ local laws and regulations.
Global Review Panel
Our gratitude to the following experts for being members of the global review panel of the 2023 program (in alphabetical order):
Adda Danjuma Kamlen
President, World Hepatitis Alliance, Nigeria
Tan Chee Kiat
Senior Consultant, Department of Gastroenterology & Hepatology, Singapore General Hospital, Singapore
Benazzouz Mustapha
Professor of Gastro-Entero-Hepatology, International Clinic Riad Annakhil, Morocco
Thomas Caroline
Founder, Peduli Hati Bangsa Foundation, Indonesia
Contreras Fernando
President, Centro de Gastroenterología Avanzada, Santo Domingo, Dominican Republic
Wei Lai
Dean and Professor, Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, China Mainland
Dao Viet Hang
Vice General Secretary, Vietnam Association of Gastroenterology, Vietnam
Yang Hwai-I
Deputy Director, Genomics Research Center, Academia Sinica, Taiwan
Hasanoglu Imran
Assoc. Prof., Ankara Bilkent City Hospital, Turkey
Yim Hyung-Joon
Professor, Division of Gastroenterology and Hepatology, Korea University Ansan Hospital, South Korea
Nakamoto Yasunari
Professor and Head, Second Department of Internal Medicine, University of Fukui, Japan
Yuen Man Fung
Chief of Division of Gastroenterology and Hepatology, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR